RayKnowChina Research Map
Shortlist

BeijingPeking University Health Science Center

Peking University Third Hospital

北京大学第三医院

Listed for 26 of the 53 diseases this site covers, from the research papers it led and the trials registered with it as lead sponsor or site.

Research activity in public records, not a rating of care. Whether the hospital can help a particular patient is for the hospital and the treating doctor to say.

Official links opened and checked on 2026-11-08.

Getting in touch

Research at Peking University Third Hospital

Choose a disease to see the papers and trials behind it. Each tile shows papers led, 2021–2025, and papers per year.

Only the 53 diseases this site covers. A disease it is not listed for means this hospital did not meet the listing rule for that disease in these records; it does not mean the hospital does not treat it. Which hospitals are listed

  1. Hepatocellular carcinoma肝细胞癌11 papers led1 open trial led
  2. Stomach cancer胃癌24 papers led2 open trials led
  3. Chordoma脊索瘤6 papers led
  4. Osteosarcoma骨肉瘤7 papers led
  5. Gastrointestinal stromal tumour胃肠道间质瘤2 papers led
  6. Neuroblastoma神经母细胞瘤0 papers led
  7. Ewing sarcoma尤文肉瘤0 papers led
  8. Multiple myeloma多发性骨髓瘤5 papers led
  9. B-cell acute lymphoblastic leukaemiaB 细胞急性淋巴细胞白血病0 papers led
  10. Beta thalassaemiaβ 地中海贫血0 papers led
  11. Haemophilia A血友病 A1 paper led
  12. Thrombotic thrombocytopenic purpura血栓性血小板减少性紫癜0 papers led
  13. Neuromyelitis optica spectrum disorder视神经脊髓炎谱系疾病2 papers led
  14. IgG4-related diseaseIgG4相关性疾病2 papers led
  15. Moyamoya disease烟雾病2 papers led
  16. Takayasu arteritis大动脉炎1 paper led
  17. Hepatic echinococcosis肝包虫病0 papers led
  18. Idiopathic pulmonary fibrosis特发性肺纤维化2 papers led
  19. Amyotrophic lateral sclerosis肌萎缩侧索硬化症52 papers led2 open trials led
  20. Spinal muscular atrophy脊髓性肌萎缩症0 papers led1 open trial led
  21. Fabry disease法布雷病1 paper led
  22. Duchenne muscular dystrophy杜氏肌营养不良1 paper led
  23. Behçet disease白塞病0 papers led
  24. IgA nephropathyIgA 肾病1 paper led
  25. Primary biliary cholangitis原发性胆汁性胆管炎0 papers led
  26. Familial adenomatous polyposis家族性腺瘤性息肉病0 papers led

Not listed for: Nasopharyngeal carcinoma, Oesophageal squamous cell carcinoma, Hepatoblastoma, Retinoblastoma, Aplastic anaemia, Haemophagocytic lymphohistiocytosis, Atypical haemolytic uraemic syndrome, Fanconi anaemia, Myasthenia gravis, Wilson disease, Biliary atresia, Anti-NMDA receptor encephalitis, Lymphangioleiomyomatosis, Pompe disease, Alport syndrome, Gaucher disease, Niemann–Pick disease type C, Osteogenesis imperfecta, Primary sclerosing cholangitis, Congenital diaphragmatic hernia, Hirschsprung disease, Inherited epidermolysis bullosa, Hereditary angioedema, Leber hereditary optic neuropathy, Majeed syndrome, NGLY1 deficiency, ISG15 deficiency.

Cancer

Hepatocellular carcinoma

肝细胞癌

Led 11 of the 14,765 English-language PubMed papers on hepatocellular carcinoma with an author in mainland China, 2021–2025: 0.07%.

Papers led
11
2021–2025
Trials led
2
any status, ClinicalTrials.gov
Open trials led
1
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 1120222023: 3320232024: 4420242025: 332025

17 hospitals in Beijing for hepatocellular carcinoma192 hospitals in China for hepatocellular carcinoma

Open trials with this hospital 1

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    68Ga-SorB PET/CT Imaging in Patients With Solid Tumors
    Phase
    N/A
    Started
    2026-08
    Registry
    NCT07760012

    Age 18 years to Not stated (registered criteria)

    Led by Peking University Third HospitalBeijing

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
ThemesRecurrence & prognosisImmunotherapy & targeted drugsRadiotherapy
Departments in papersRadiation oncologySurgery (general/hepatobiliary/pancreatic)Gastroenterology / hepatologyPathology / laboratory medicine

Over half of these papers are lab or animal studies.

Papers it led11
  1. Expression and prognostic significance of MLH1 and GPRC5C in resectable hepatocellular carcinoma.2025BMC cancerFree full text
  2. Sorafenib enhanced the function of myeloid-derived suppressor cells in hepatocellular carcinoma by facilitating PPARα-mediated fatty acid oxidation.2025Molecular cancerFree full text
  3. Stereotactic radiotherapy with Gamma Master System® for palliation of hepatocellular carcinoma in patients with liver cirrhosis.2025Radiation oncology (London, England)Free full text
  4. SPINK1 Overexpression Correlates with Hepatocellular Carcinoma Treatment Resistance Revealed by Single Cell RNA-Sequencing and Spatial Transcriptomics.2024BiomoleculesFree full text
  5. Prognostic Value of N1/N2 Neutrophils Heterogeneity and Tertiary Lymphoid Structure in Hepatocellular Carcinoma Patients.2024Cancer medicineFree full text
  6. CMTM7 shapes the chronic inflammatory and immunosuppressive tumor microenvironment in hepatocellular carcinoma as an M2 macrophage biomarker.2024Scientific reportsFree full text
  7. Cytoskeletal gene alterations linked to sorafenib resistance in hepatocellular carcinoma.2024World journal of surgical oncologyFree full text
  8. Target immune components to circumvent sorafenib resistance in hepatocellular carcinoma.2023Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
  9. Allosteric regulation of the lid domain of PCK2 as a novel strategy for modulating mitochondrial dynamics.2023Chemical communications (Cambridge, England)
  10. Advances in radiotherapy and immunity in hepatocellular carcinoma.2023Journal of translational medicineFree full text
  11. Peroxisome-related genes in hepatocellular carcinoma correlated with tumor metabolism and overall survival.2022Clinics and research in hepatology and gastroenterology
All its trials on ClinicalTrials.gov, any status2
  1. 68Ga-SorB PET/CT Imaging in Patients With Solid TumorsRecruitingNCT07760012Lead sponsorN/AStart 2026-08
  2. Assessment of Remnant Liver Function in ALPPS by Gd-EOB-DTPA Enhanced MRIStatus unknownNCT04559451Lead sponsorStart 2020-10

Run the PubMed searchClinicalTrials.gov

Cancer

Stomach cancer

胃癌

Led 24 of the 9,782 English-language PubMed papers on stomach cancer with an author in mainland China, 2021–2025: 0.2%.

Papers led
24
2021–2025
Trials led
4
any status, ClinicalTrials.gov
Open trials led
2
recruiting or about to
Open trials as a site
2
led by another institution
Papers led per year
2021: 2220212022: 9920222023: 4420232024: 3320242025: 662025

15 hospitals in Beijing for stomach cancer218 hospitals in China for stomach cancer

Open trials with this hospital 4

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    PD-1 Antibody Carilizumab Combined with Apatinib for Unresectable Stage III and IV DMMR Gastric Cancer
    Phase
    Phase 2
    Started
    2023-04
    Registry
    NCT06792162

    Age 18 years to Not stated (registered criteria)

    Led by Peking University Third HospitalBeijing

  2. Not yet recruiting
    Endoscopic Submucosal Dissection Versus Surgery in the Treatment of Early Gastric Cancer
    Phase
    N/A
    Started
    2019-03
    Registry
    NCT03857737

    Age not stated (registered criteria)

    Led by Peking University Third HospitalBeijing

  3. Recruiting
    Oral Paclitaxel Plus Fruquintinib Verus Investigator's Choice in Second-Line Advanced Gastric Cancer
    Phase
    N/A
    Started
    2026-06
    Registry
    NCT07552402

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 10 listed hospitals as study sitesBeijing, Chengdu, Fuzhou, Hangzhou, Nanning, Shanghai, Shijiazhuang, Suzhou, Wuhan, Yinchuan

  4. Recruiting
    Study of TDXd, Chemotherapy, Pembrolizumab, and Trastuzumab in First-Line Metastatic HER2-Positive Gastric or Gastroesophageal Junction Cancer
    Phase
    Phase 3
    Started
    2025-02
    Registry
    NCT06731478

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 23 listed hospitals as study sitesBeijing, Changzhou, Fuzhou, Hangzhou, Harbin, Hefei, Jinan, Lanzhou, Linyi, Shanghai, Shenyang, Suzhou, Taiyuan, Tianjin, Urumqi, Wuhan, Xi'an, Xiamen, Xuzhou, Yinchuan, Zhengzhou

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
ThemesEarly detection & endoscopyImmunotherapy & targeted drugsImaging & AI
Departments in papersGastroenterology / hepatologyRadiology / nuclear medicineSurgery (general/hepatobiliary/pancreatic)Pathology / laboratory medicine
Papers it led24
  1. Helicobacter pylori infection status and evolution of gastric cancer.2025Chinese medical journalFree full text
  2. Dynamic changes of host immune response during Helicobacter pylori-induced gastric cancer development.2025Clinical and experimental immunology
  3. Luteolin improves precancerous conditions of the gastric mucosa by binding STAT3 and inhibiting LCN2 expression.2025International journal of biological sciencesFree full text
  4. Ultrasound-triggered topical oxygen delivery enhances synergistic sonodynamic and antibody therapies against hypoxic gastric cancer.2025Journal of controlled release : official journal of the Controlled Release Society
  5. Cmtm4 Deficiency Inhibits Helicobacter pylori-Induced Gastric Carcinogenesis.2025Pathology international
  6. Raman spectroscopy and machine learning for early detection of gastric cancer and Helicobacter pylori with gastric juice.2025Scientific reportsFree full text
  7. YAP inhibition overcomes adaptive resistance in HER2-positive gastric cancer treated with trastuzumab via the AKT/mTOR and ERK/mTOR axis.2024Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer AssociationFree full text
  8. Helicobacter pylori with trx1 high expression promotes gastric diseases via upregulating the IL23A/NF-κB/IL8 pathway.2024Helicobacter
  9. Machine learning models to predict submucosal invasion in early gastric cancer based on endoscopy features and standardized color metrics.2024Scientific reportsFree full text
  10. Patient-derived organoid culture of gastric cancer for disease modeling and drug sensitivity testing.2023Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
  11. Long-term outcomes of additional surgery versus non-gastrectomy treatment for early gastric cancer after non-curative endoscopic submucosal dissection: a meta-analysis.2023Chinese medical journalFree full text
  12. The expression and function of the B7 family in Helicobacter pylori infection and gastric carcinogenesis process.2023Helicobacter
  13. Antitumor effect of luteolin proven by patient-derived organoids of gastric cancer.2023Phytotherapy research : PTR
  14. Ultrasound Microbubbles Mediated Sonosensitizer and Antibody Co-delivery for Highly Efficient Synergistic Therapy on HER2-Positive Gastric Cancer.2022ACS applied materials & interfaces
  15. Double contrast-enhanced ultrasound for the preoperative gross classification of gastric cancer: a comparison with multidetector computed tomography.2022BMC medical imagingFree full text
  16. Epigenetic modification facilitates proline synthase PYCR1 aberrant expression in gastric cancer.2022Biochimica et biophysica acta. Gene regulatory mechanisms
  17. Traditional Chinese medicine for precancerous lesions of gastric cancer: A review.2022Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
  18. Long-Term Outcome of Gastric Mild-Moderate Dysplasia: A Real-World Clinical Experience.2022Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association
  19. Combining single-cell sequencing data to construct a prognostic signature to predict survival, immune microenvironment, and immunotherapy response in gastric cancer patients.2022Frontiers in immunologyFree full text
  20. Effect of Helicobacter pylori on immunotherapy is gaining more attention.2022Helicobacter
  21. Influence of Helicobacter pylori infection on PD-1/PD-L1 blockade therapy needs more attention.2022Helicobacter
  22. Microbiome changes in the gastric mucosa and gastric juice in different histological stages of Helicobacter pylori-negative gastric cancers.2022World journal of gastroenterologyFree full text
  23. Downregulation of FABP5 Suppresses the Proliferation and Induces the Apoptosis of Gastric Cancer Cells Through the Hippo Signaling Pathway.2021DNA and cell biology
  24. Endoscopic grading of gastric atrophy on risk assessment of gastric neoplasia: A systematic review and meta-analysis.2021Journal of gastroenterology and hepatology
Chinese-language papers (not in the count)1
  1. [Analysis of endoscopic and pathological features of gastric adenomatous polyps and risk factors for canceration].2021Beijing da xue xue bao. Yi xue ban = Journal of Peking University. Health sciencesFree full text
All its trials on ClinicalTrials.gov, any status13
  1. PD-1 Antibody Carilizumab Combined with Apatinib for Unresectable Stage III and IV DMMR Gastric CancerRecruitingNCT06792162Lead sponsorPhase 2Start 2023-04
  2. Endoscopic Submucosal Dissection Versus Surgery in the Treatment of Early Gastric CancerNot yet recruitingNCT03857737Lead sponsorN/AStart 2019-03
  3. Evaluation of the Preventive Effect of Chlorhexidine Acetate Gargle for Upper Gastrointestinal Tract Infection After ESDStatus unknownNCT03492827Lead sponsorN/AStart 2017-06
  4. Predictive Factors for Roux Stasis SyndromeCompletedNCT04919577Lead sponsorStart 2014-03
  5. Oral Paclitaxel Plus Fruquintinib Verus Investigator's Choice in Second-Line Advanced Gastric CancerRecruitingNCT07552402Study siteN/AStart 2026-06
  6. Study of TDXd, Chemotherapy, Pembrolizumab, and Trastuzumab in First-Line Metastatic HER2-Positive Gastric or Gastroesophageal Junction CancerRecruitingNCT06731478Study sitePhase 3Start 2025-02
  7. To Evaluate Efficacy and Safety of TT-00420 (Tinengotinib) as Monotherapy and Combination Therapy in Patients With Advanced Solid TumorsCompletedNCT05253053Study sitePhase 1/Phase 2Start 2022-04
  8. Study to Assess the Efficacy and Safety of Lanreotide Autogel® in Chinese Participants With GEP-NETsCompletedNCT04852679Study sitePhase 3Start 2021-05
  9. A Study of Zanidatamab in Combination With Chemotherapy Plus or Minus Tislelizumab in Patients With HER2-positive Advanced or Metastatic Gastric and Esophageal CancersActive, not recruitingNCT05152147Study sitePhase 3Start 2021-12
  10. Phase I-II, FIH, TROP2 ADC, Advanced Unresectable/Metastatic Solid Tumors, Refractory to Standard Therapies (KL264-01)Active, not recruitingNCT04152499Study sitePhase 1/Phase 2Start 2020-02
  11. HX008 Plus Irinotecan Versus Placebo Plus Irinotecan as Second-line Treatment in Advanced Gastric CancerStatus unknownNCT04486651Study sitePhase 3Start 2020-09
  12. A Clinical Study of HLX10 Combined With Chemotherapy Versus Placebo Combined With Chemotherapy for Neoadjuvant/Adjuvant Treatment of Gastric CancerStatus unknownNCT04139135Study sitePhase 3Start 2019-12
  13. A Non-Interventional Study of Treatment Pattern and Clinical Outcomes in Chinese Participants With Gastric CancerCompletedNCT01839500Study siteStart 2013-04

Run the PubMed searchClinicalTrials.gov

Cancer

Chordoma

脊索瘤

Led 6 of the 105 English-language PubMed papers on chordoma with an author in mainland China, 2021–2025: 5.7%.

Papers led
6
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 1120222023: 0020232024: 3320242025: 222025

11 hospitals in Beijing for chordoma88 hospitals in China for chordoma

No open trial on chordoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersNeurosurgeryRadiology / nuclear medicine
Papers it led6
  1. Cracking Chordoma's Conundrum: Immune Checkpoints Provide a Potential Modality.2025International journal of medical sciences
  2. SMARCB1 orchestrates cellular plasticity and oncogenic pathways in typical and chondroid chordomas.2025Scientific reports
  3. Misdiagnosis of primary dumbbell chordoma of the cervical spine.2024Asia-Pacific journal of clinical oncology
  4. Complications and local recurrence of chondrosarcoma and chordoma treated by total tumor resection in thoracic and lumbar spine.2024BMC musculoskeletal disorders
  5. Hypoxia-Inducible Factor-1α (HIF-1α) as a Factor to Predict the Prognosis of Spinal Chordoma.2024Spine
  6. Preliminary study of monoexponential, biexponential, and stretched-exponential models of diffusion-weighted MRI and diffusion kurtosis imaging on differential diagnosis of spinal metastases and chordoma.2022European spine journal : official publication of the European Spine Society, the European Spinal Deformity Society, and the European Section of the Cervical Spine Research Society
Earlier papers (2016–2020)9
  1. Cytotoxic T lymphocyte antigen-4 (CTLA-4) expression in chordoma and tumor-infiltrating lymphocytes (TILs) predicts prognosis of spinal chordoma.2020Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
  2. Set-up error and dosimetric analysis of HexaPOD evo RT 6D couch combined with cone beam CT image-guided intensity-modulated radiotherapy for primary malignant tumor of the cervical spine.2020Journal of applied clinical medical physics
  3. Genetic landscape and ligand-dependent activation of sonic hedgehog-Gli1 signaling in chordomas: a novel therapeutic target.2020Oncogene
  4. [Anesthesia management of cervical chordoma resection: A case report].2019Beijing da xue xue bao. Yi xue ban = Journal of Peking University. Health sciences
  5. Y-box binding protein-1 promotes tumorigenesis and progression via the epidermal growth factor receptor/AKT pathway in spinal chordoma.2019Cancer science
  6. A brief review of chordomas: pathogenesis, prognostic factors and therapeutic targets.2019Histology and histopathology
  7. Radiofrequency ablation in gross total excision of cervical chordoma: ideas and technique.2018European spine journal : official publication of the European Spine Society, the European Spinal Deformity Society, and the European Section of the Cervical Spine Research Society
  8. Prognostic Factors in Surgical Patients with Chordomas of the Cervical Spine: A Study of 52 Cases from a Single Institution.2017Annals of surgical oncology
  9. Morphological and dynamic contrast enhanced MR imaging features for the differentiation of chordoma and giant cell tumors in the Axial Skeleton.2017Journal of magnetic resonance imaging : JMRI

Run the PubMed searchClinicalTrials.gov

Cancer

Osteosarcoma

骨肉瘤

Led 7 of the 2,257 English-language PubMed papers on osteosarcoma with an author in mainland China, 2021–2025: 0.3%.

Papers led
7
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 2220212022: 1120222023: 1120232024: 3320242025: 002025

48 hospitals in Beijing for osteosarcoma742 hospitals in China for osteosarcoma

No open trial on osteosarcoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Over half of these papers are lab or animal studies.

Papers it led7
  1. Arnicolide D Inhibits Proliferation and Induces Apoptosis of Osteosarcoma Cells through PI3K/Akt/mTOR Pathway.2024Anti-cancer agents in medicinal chemistry
  2. Metabolic Landscape of Osteosarcoma: Reprogramming of Lactic Acid Metabolism and Metabolic Communication.2024Frontiers in bioscience (Landmark edition)
  3. Transcriptome and single-cell analysis reveal disulfidptosis-related modification patterns of tumor microenvironment and prognosis in osteosarcoma.2024Scientific reports
  4. The Dilemma of Balance between Benefits and Losses for Chondromyxoid Fibroma-like Osteosarcoma in Thoracic Spine with Azygos Tumor Thrombosis: A Case Report.2023Medicina (Kaunas, Lithuania)
  5. Liensinine Inhibits Osteosarcoma Growth by ROS-Mediated Suppression of the JAK2/STAT3 Signaling Pathway.2022Oxidative medicine and cellular longevity
  6. D-arginine-loaded metal-organic frameworks nanoparticles sensitize osteosarcoma to radiotherapy.2021Biomaterials
  7. VPS34 regulates dynamin to determine the endocytosis of mitochondria-targeted zinc oxide nanoparticles in human osteosarcoma cells.2021Journal of materials chemistry. B
Chinese-language papers (not in the count)1
  1. [Experience in diagnosis and treatment of 6 cases of renal Ewing's sarcoma with venous thrombus].2024Beijing da xue xue bao. Yi xue ban = Journal of Peking University. Health sciences
Earlier papers (2016–2020)9
  1. HIF-1α-Mediated Mitophagy Determines ZnO Nanoparticle-Induced Human Osteosarcoma Cell Death both In Vitro and In Vivo.2020ACS applied materials & interfaces
  2. Set-up error and dosimetric analysis of HexaPOD evo RT 6D couch combined with cone beam CT image-guided intensity-modulated radiotherapy for primary malignant tumor of the cervical spine.2020Journal of applied clinical medical physics
  3. Oleandrin sensitizes human osteosarcoma cells to cisplatin by preventing degradation of the copper transporter 1.2019Phytotherapy research : PTR
  4. Cross Talk Between Autophagy and Apoptosis Contributes to ZnO Nanoparticle-Induced Human Osteosarcoma Cell Death.2018Advanced healthcare materials
  5. Oleandrin synergizes with cisplatin in human osteosarcoma cells by enhancing cell apoptosis through activation of the p38 MAPK signaling pathway.2018Cancer chemotherapy and pharmacology
  6. Renal Ewing's sarcoma/primitive neuroectodermal tumor: a case report and literature review.2017Beijing da xue xue bao. Yi xue ban = Journal of Peking University. Health sciences
  7. Recurrence Factors in Giant Cell Tumors of the Spine.2017Chinese medical journal
  8. Molecular Heterogeneity of Ewing Sarcoma as Detected by Ion Torrent Sequencing.2016PloS one
  9. Reconstruction of the Upper Cervical Spine Using a Personalized 3D-Printed Vertebral Body in an Adolescent With Ewing Sarcoma.2016Spine

Run the PubMed searchClinicalTrials.gov

Cancer

Gastrointestinal stromal tumour

胃肠道间质瘤

Led 2 of the 523 English-language PubMed papers on gastrointestinal stromal tumour with an author in mainland China, 2021–2025: 0.4%.

Papers led
2
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 1120232024: 1120242025: 002025

23 hospitals in Beijing for gastrointestinal stromal tumour261 hospitals in China for gastrointestinal stromal tumour

No open trial on gastrointestinal stromal tumour lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersPathology / laboratory medicineSurgery (general/hepatobiliary/pancreatic)

Run the PubMed searchClinicalTrials.gov

Cancer

Neuroblastoma

神经母细胞瘤

Led no English-language PubMed papers on neuroblastoma in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution

24 hospitals in Beijing for neuroblastoma352 hospitals in China for neuroblastoma

No open trial on neuroblastoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersPathology / laboratory medicine
Chinese-language papers (not in the count)1
  1. [Advances in the clinicopathological research of undifferentiated and dedifferentiated endometrial carcinoma].2022Zhonghua bing li xue za zhi = Chinese journal of pathology

Run the PubMed searchClinicalTrials.gov

Cancer

Ewing sarcoma

尤文肉瘤

Led no English-language PubMed papers on Ewing sarcoma in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution

17 hospitals in Beijing for Ewing sarcoma139 hospitals in China for Ewing sarcoma

No open trial on Ewing sarcoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Chinese-language papers (not in the count)1
  1. [Experience in diagnosis and treatment of 6 cases of renal Ewing's sarcoma with venous thrombus].2024Beijing da xue xue bao. Yi xue ban = Journal of Peking University. Health sciences
Earlier papers (2016–2020)3
  1. Renal Ewing's sarcoma/primitive neuroectodermal tumor: a case report and literature review.2017Beijing da xue xue bao. Yi xue ban = Journal of Peking University. Health sciences
  2. Molecular Heterogeneity of Ewing Sarcoma as Detected by Ion Torrent Sequencing.2016PloS one
  3. Reconstruction of the Upper Cervical Spine Using a Personalized 3D-Printed Vertebral Body in an Adolescent With Ewing Sarcoma.2016Spine
All its trials on ClinicalTrials.gov, any status1
  1. Anlotinib and Irinotecan for Ewing SarcomaStatus unknownNCT03416517Study sitePhase 1/Phase 2Start 2018-01

Run the PubMed searchClinicalTrials.gov

Blood disorders

Multiple myeloma

多发性骨髓瘤

Led 5 of the 1,676 English-language PubMed papers on multiple myeloma with an author in mainland China, 2021–2025: 0.3%.

Papers led
5
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
10
led by another institution
Papers led per year
2021: 2220212022: 2220222023: 0020232024: 0020242025: 112025

15 hospitals in Beijing for multiple myeloma178 hospitals in China for multiple myeloma

Open trials with this hospital 10

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    A Study to Compare the PK Characteristics, Safety, Tolerability, and Immunogenicity of HLX15-SC With DARZALEX FASPRO® in Combination With Lenalidomide and Dexamethasone (Rd) in Transplant-ineligible Patients With Newly Diagnosed Multiple Myeloma
    Phase
    Phase 1
    Started
    2026-05
    Registry
    NCT07477587

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 46 listed hospitals as study sitesBeijing, Bengbu, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Guiyang, Hangzhou, Harbin, Hefei, Jinan, Nanchang, Nanjing, Ningbo, Qingdao, Shanghai, Shenyang, Shenzhen, Shijiazhuang, Suzhou, Taiyuan, Tianjin, Weifang, Wenzhou, Wuhan, Wuxi, Xiamen, Xuzhou, Zhengzhou

  2. Recruiting
    Safety and Efficacy Study of An Anti-CD38 Antibody Drug Conjugate in Relapsed or Refractory Multiple Myeloma
    Phase
    Phase 1/Phase 2
    Started
    2023-02
    Registry
    NCT05565807

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 3 listed hospitals as study sitesBeijing, Hangzhou

  3. Recruiting
    Elranatamab Post Trial Access Study for Participants With Multiple Myeloma (MM)
    Phase
    Phase 4
    Started
    2023-10
    Registry
    NCT06057402

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 4 listed hospitals as study sitesBeijing, Guangzhou, Hangzhou, Jinan

  4. Recruiting
    A Long-term Study for Participants Previously Treated With Ciltacabtagene Autoleucel
    Phase
    Phase 4
    Started
    2022-03
    Registry
    NCT05201781

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 10 listed hospitals as study sitesBeijing, Chengdu, Fuzhou, Guangzhou, Hangzhou, Nanjing, Shanghai, Xi'an

  5. Recruiting
    Mecapegfilgrastim With Chemotherapy for Peripheral Blood Stem Cell Mobilization in MM and Lymphoma
    Phase
    Phase 2
    Started
    2022-04
    Registry
    NCT05294055

    Age 18 years to 65 years (registered criteria)

    Led by Institute of Hematology & Blood Diseases Hospital, CAMS & PUMC; 6 listed hospitals as study sitesBeijing, Hefei, Jinan, Tianjin, Zhengzhou

  6. Recruiting
    A Study of CM336 in Patients With Relapsed or Refractory Multiple Myeloma
    Phase
    Phase 1/Phase 2
    Started
    2022-08
    Registry
    NCT05299424

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing

  7. Recruiting
    A Study to Learn About the Effects of the Combination of Elranatamab, Daratumumab and Lenalidomide Compared With Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Who Are Not Candidates for Transplant
    Phase
    Phase 3
    Started
    2022-11
    Registry
    NCT05623020

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 12 listed hospitals as study sitesBeijing, Changchun, Fuzhou, Guangzhou, Hangzhou, Nanjing, Shanghai, Suzhou, Tianjin, Wenzhou, Wuhan

  8. Recruiting
    A Study of Talquetamab in Participants With Relapsed or Refractory Multiple Myeloma
    Phase
    Phase 2
    Started
    2021-02
    Registry
    NCT04634552

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 5 listed hospitals as study sitesBeijing, Suzhou, Tianjin, Xi'an

  9. Recruiting
    A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple Myeloma
    Phase
    Phase 1/Phase 2
    Started
    2021-09
    Registry
    NCT04973605

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 19 listed hospitals as study sitesBeijing, Changsha, Chongqing, Fuzhou, Hangzhou, Nanchang, Nanjing, Qingdao, Shanghai, Shenyang, Shijiazhuang, Tianjin, Wuhan, Xiamen, Zhengzhou

  10. Recruiting
    A Study to Learn About the Study Medicine Elranatamab Alone and With Daratumumab in People With Multiple Myeloma Who Have Received Other Treatments
    Phase
    Phase 3
    Started
    2021-10
    Registry
    NCT05020236

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 20 listed hospitals as study sitesBeijing, Changchun, Chongqing, Fuzhou, Guangzhou, Hangzhou, Jinan, Nanchang, Nanjing, Shenzhen, Shijiazhuang, Tianjin, Wenzhou, Wuhan, Xuzhou, Zhengzhou

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
ThemesDrug combinationsDiagnosis, MRD & riskKidney & bone complications
Departments in papersRadiology / nuclear medicine
Papers it led5
  1. Push Forward Clinical Management of Hematological Toxicity due to Lenalidomide Overexposure: Model-Informed Precision Dosing for Chinese Population With Renal Insufficiency.2025CPT: pharmacometrics & systems pharmacologyFree full text
  2. Safety and efficacy of daratumumab in Chinese patients with relapsed or refractory multiple myeloma: a phase 1, dose-escalation study (MMY1003).2022Annals of hematologyFree full text
  3. Vertebral MRI-based radiomics model to differentiate multiple myeloma from metastases: influence of features number on logistic regression model performance.2022European radiology
  4. Prediction of High-Risk Cytogenetic Status in Multiple Myeloma Based on Magnetic Resonance Imaging: Utility of Radiomics and Comparison of Machine Learning Methods.2021Journal of magnetic resonance imaging : JMRI
  5. A preliminary study using spinal MRI-based radiomics to predict high-risk cytogenetic abnormalities in multiple myeloma.2021La Radiologia medica
Chinese-language papers (not in the count)2
  1. [The Pathogenesis and Treatment Progress of Extramedullary Multiple Myeloma --Review].2025Zhongguo shi yan xue ye xue za zhi
  2. [Detection of cytogenetic abnormalities in multiple myeloma by using optical genome mapping].2024Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhiFree full text
All its trials on ClinicalTrials.gov, any status32
  1. A Study to Compare the PK Characteristics, Safety, Tolerability, and Immunogenicity of HLX15-SC With DARZALEX FASPRO® in Combination With Lenalidomide and Dexamethasone (Rd) in Transplant-ineligible Patients With Newly Diagnosed Multiple MyelomaRecruitingNCT07477587Study sitePhase 1Start 2026-05
  2. Elranatamab Post Trial Access Study for Participants With Multiple Myeloma (MM)RecruitingNCT06057402Study sitePhase 4Start 2023-10
  3. Safety and Efficacy Study of An Anti-CD38 Antibody Drug Conjugate in Relapsed or Refractory Multiple MyelomaRecruitingNCT05565807Study sitePhase 1/Phase 2Start 2023-02
  4. A Study of CM336 in Patients With Relapsed or Refractory Multiple MyelomaRecruitingNCT05299424Study sitePhase 1/Phase 2Start 2022-08
  5. A Study to Learn About the Effects of the Combination of Elranatamab, Daratumumab and Lenalidomide Compared With Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Who Are Not Candidates for TransplantRecruitingNCT05623020Study sitePhase 3Start 2022-11
  6. A Long-term Study for Participants Previously Treated With Ciltacabtagene AutoleucelRecruitingNCT05201781Study sitePhase 4Start 2022-03
  7. Mecapegfilgrastim With Chemotherapy for Peripheral Blood Stem Cell Mobilization in MM and LymphomaRecruitingNCT05294055Study sitePhase 2Start 2022-04
  8. A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple MyelomaRecruitingNCT04973605Study sitePhase 1/Phase 2Start 2021-09
  9. A Study of Talquetamab in Participants With Relapsed or Refractory Multiple MyelomaRecruitingNCT04634552Study sitePhase 2Start 2021-02
  10. A Study to Learn About the Study Medicine Elranatamab Alone and With Daratumumab in People With Multiple Myeloma Who Have Received Other TreatmentsRecruitingNCT05020236Study sitePhase 3Start 2021-10
  11. A Phase III Study of Eque-cel in Subjects With Len-refractory RRMM (FUMANBA-03)Active, not recruitingNCT06464991Study sitePhase 3Start 2024-03
  12. A Study of the Efficacy and Safety of Pomalidomide Capsules Combined With Low-Dose Dexamethasone in Subjects With Relapsed and Refractory Multiple MyelomaStatus unknownNCT05236621Study sitePhase 3Start 2021-01
  13. A Study of Elranatamab (PF-06863135) in Chinese Participants With Refractory Multiple Myeloma.CompletedNCT05228470Study sitePhase 2Start 2021-12
  14. Dose Escalation and Expansion Study of CM313 in Subjects With Relapsed or Refractory Multiple Myeloma and LymphomaStatus unknownNCT04818372Study sitePhase 1Start 2021-04
  15. A Study of Teclistamab in Combination With Daratumumab Subcutaneously (SC) (Tec-Dara) Versus Daratumumab SC, Pomalidomide, and Dexamethasone (DPd) or Daratumumab SC, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple MyelomaActive, not recruitingNCT05083169Study sitePhase 3Start 2021-10
  16. A Study of Ninlaro in Real World Clinical Practice in ChinaCompletedNCT04328662Study siteStart 2020-05
  17. Clinical Trial to Evaluate CT053 in Patients With Relapsed and/or Refractory Multiple Myeloma (LUMMICAR STUDY 1)Status unknownNCT03975907Study sitePhase 1/Phase 2Start 2019-06
  18. A Study of LCAR-B38M CAR-T Cells, a Chimeric Antigen Receptor T-cell (CAR-T) Therapy Directed Against B-cell Maturation Antigen (BCMA) in Chinese Participants With Relapsed or Refractory Multiple MyelomaTerminatedNCT03758417Study sitePhase 2Start 2019-01
  19. A Study of Subcutaneous Delivery of JNJ-54767414 in Chinese Participants With Multiple MyelomaCompletedNCT04121260Study sitePhase 1Start 2019-12
  20. Study of Oral Ixazomib Maintenance Therapy After Initial Therapy in Participants With Newly Diagnosed Multiple Myeloma Not Treated With Stem Cell Transplantation (SCT)CompletedNCT03748953Study sitePhase 3Start 2019-01
  21. A Study of Evaluating the Safety and Efficacy of ATG-010 in Relapsed Refractory Multiple MyelomaCompletedNCT03944057Study sitePhase 2Start 2019-09
  22. TJ202, Lenalidomide and Dexamethasone vs. Lenalidomide and Dexamethasone in Subjects With Relapsed or Refractory Multiple MyelomaCompletedNCT03952091Study sitePhase 3Start 2019-03
  23. A Study Designed to Evaluate the Safety and Efficacy of Venetoclax Plus Dexamethasone (VenDex) Compared With Pomalidomide Plus Dexamethasone (PomDex) in Participants With t(11;14)-Positive Relapsed or Refractory Multiple Myeloma.Active, not recruitingNCT03539744Study sitePhase 3Start 2018-10
  24. A Study of Modakafusp Alfa on Adult Participants With Relapsed/Refractory Multiple MyelomaTerminatedNCT03215030Study sitePhase 1/Phase 2Start 2017-10
  25. A Study of VELCADE (Bortezomib) Melphalan-Prednisone (VMP) Compared to Daratumumab in Combination With VMP (D-VMP), in Participants With Previously Untreated Multiple Myeloma Who Are Ineligible for High-Dose Therapy (Asia Pacific Region)CompletedNCT03217812Study sitePhase 3Start 2017-11
  26. Carfilzomib in Combination With Dexamethasone (Kd) in Chinese Patients With Relapsed & Refractory Multiple MyelomaCompletedNCT03029234Study sitePhase 3Start 2017-03
  27. A Study to Compare Daratumumab, Bortezomib, and Dexamethasone (DVd) vs Bortezomib and Dexamethasone (Vd) in Chinese Participants With Relapsed or Refractory Multiple MyelomaCompletedNCT03234972Study sitePhase 3Start 2017-11
  28. Ixazomib Rollover StudyCompletedNCT02924272Study sitePhase 2Start 2016-12
  29. A Study of Oral Ixazomib Maintenance Therapy in Participants With Newly Diagnosed Multiple Myeloma (NDMM) Not Treated With Stem Cell Transplantation (SCT)CompletedNCT02312258Study sitePhase 3Start 2015-04
  30. Phase 3 Study of Carfilzomib, Melphalan, Prednisone vs Bortezomib, Melphalan, Prednisone in Newly Diagnosed Multiple MyelomaCompletedNCT01818752Study sitePhase 3Start 2013-07
  31. Open-label Extended Access Program on Lenalidomide Plus Dexamethasone in Chinese Subjects With Relapsed/Refractory Multiple Myeloma Who Participated in CC-5013-MM021 for at Least 1 YearCompletedNCT02348528Study sitePhase 2Start 2012-09
  32. Study of Lenalidomide and Low-Dose Dexamethasone in Chinese Subjects With Relapsed/Refractory Multiple MyelomaCompletedNCT01593410Study sitePhase 2Start 2010-08

Run the PubMed searchClinicalTrials.gov

Blood disorders

B-cell acute lymphoblastic leukaemia

B 细胞急性淋巴细胞白血病

Led no English-language PubMed papers on B-cell acute lymphoblastic leukaemia in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
2
led by another institution

10 hospitals in Beijing for B-cell acute lymphoblastic leukaemia90 hospitals in China for B-cell acute lymphoblastic leukaemia

Open trials with this hospital 2

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    Inaticabtagene Autoleucel Injection Treatment for Adult Relapsed or Refractory Acute Lymphocytic Leukemia
    Phase
    Not given
    Started
    2024-06
    Registry
    NCT06450067

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 10 listed hospitals as study sitesBeijing, Chengdu, Guangzhou, Jinan, Shanghai, Tianjin, Wuhan, Xuzhou, Zhengzhou

  2. Recruiting
    Phase Ib Clinical Study of Keynatinib
    Phase
    Phase 1
    Started
    2020-09
    Registry
    NCT04807881

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 3 listed hospitals as study sitesBeijing, Chengdu, Shanghai

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Blood disorders

Beta thalassaemia

β 地中海贫血

Led no English-language PubMed papers on beta thalassaemia in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution

10 hospitals in Beijing for beta thalassaemia157 hospitals in China for beta thalassaemia

No open trial on beta thalassaemia lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Chinese-language papers (not in the count)1
  1. [Analysis of Thalassemia Gene Variants in the Wuhan Region].2025Zhongguo shi yan xue ye xue za zhi

Run the PubMed searchClinicalTrials.gov

Blood disorders

Haemophilia A

血友病 A

Led 1 of the 272 English-language PubMed papers on haemophilia A with an author in mainland China, 2021–2025: 0.4%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 1120232024: 0020242025: 002025

15 hospitals in Beijing for haemophilia A160 hospitals in China for haemophilia A

No open trial on haemophilia A lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Blood disorders

Thrombotic thrombocytopenic purpura

血栓性血小板减少性紫癜

Led no English-language PubMed papers on thrombotic thrombocytopenic purpura in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution

8 hospitals in Beijing for thrombotic thrombocytopenic purpura59 hospitals in China for thrombotic thrombocytopenic purpura

No open trial on thrombotic thrombocytopenic purpura lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Other diseases

Neuromyelitis optica spectrum disorder

视神经脊髓炎谱系疾病

Led 2 of the 485 English-language PubMed papers on neuromyelitis optica spectrum disorder with an author in mainland China, 2021–2025: 0.4%.

Papers led
2
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 0020242025: 222025

12 hospitals in Beijing for neuromyelitis optica spectrum disorder67 hospitals in China for neuromyelitis optica spectrum disorder

No open trial on neuromyelitis optica spectrum disorder lists this hospital on ClinicalTrials.gov on 8 Nov 2026.

The records behind these numbers
ThemesAntibodies & diagnosisPregnancy, children, older adults
Departments in papersNeurology
Papers it led2
  1. Microglial estrogen receptor 1 signal designates sexual dimorphism of AQP4 antibody-induced neuroinflammation and demyelination.2025Cell reports
  2. Clinical characteristics of late-onset neuromyelitis optica spectrum disorder in China.2025Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia
More papers found outside PubMed (not counted)1
  1. The clinical characteristics of neuromyelitis optica spectrum disorders with other autoimmune diseases2022DOAJ (DOAJ: Directory of Open Access Journals)article

Run the PubMed searchClinicalTrials.gov

Other diseases

IgG4-related disease

IgG4相关性疾病

Led 2 of the 246 English-language PubMed papers on IgG4-related disease with an author in mainland China, 2021–2025: 0.8%.

Papers led
2
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 1120232024: 1120242025: 002025

11 hospitals in Beijing for IgG4-related disease46 hospitals in China for IgG4-related disease

No open trial on IgG4-related disease lists this hospital on ClinicalTrials.gov on 8 Nov 2026.

The records behind these numbers
ThemesTreatment & relapseDiagnosis & look-alikes
Departments in papersRheumatology & immunologyPathology / laboratory medicine

Run the PubMed searchClinicalTrials.gov

Other diseases

Moyamoya disease

烟雾病

Led 2 of the 356 English-language PubMed papers on moyamoya disease with an author in mainland China, 2021–2025: 0.6%.

Papers led
2
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 0020242025: 222025

8 hospitals in Beijing for moyamoya disease47 hospitals in China for moyamoya disease

No open trial on moyamoya disease lists this hospital on ClinicalTrials.gov on 8 Nov 2026.

The records behind these numbers
ThemesGeneticsImaging & blood flow
Departments in papersNeurology

Run the PubMed searchClinicalTrials.gov

Other diseases

Takayasu arteritis

大动脉炎

Led 1 of the 187 English-language PubMed papers on Takayasu arteritis with an author in mainland China, 2021–2025: 0.5%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 1120232024: 0020242025: 002025

30 hospitals in Beijing for Takayasu arteritis108 hospitals in China for Takayasu arteritis

No open trial on Takayasu arteritis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersRheumatology & immunologyRadiology / nuclear medicine
Papers it led1
  1. The performance of the 2022 ACR/EULAR classification criteria for Takayasu's arteritis as compared to the 1990 ACR classification criteria in a Chinese population.2023Clinical and experimental medicine
Chinese-language papers (not in the count)1
  1. [Comparison of diagnostic efficacy of different classification criteria for Takayasu arteritis in Chinese patients].2022Beijing da xue xue bao. Yi xue ban = Journal of Peking University. Health sciences
Earlier papers (2016–2020)1
  1. [Anesthesia management of caesarean section for pregnant women complicated with Takayasu's arteritis].2016Beijing da xue xue bao. Yi xue ban = Journal of Peking University. Health sciences

Run the PubMed searchClinicalTrials.gov

Other diseases

Hepatic echinococcosis

肝包虫病

Led no English-language PubMed papers on hepatic echinococcosis in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution

6 hospitals in Beijing for hepatic echinococcosis49 hospitals in China for hepatic echinococcosis

No open trial on hepatic echinococcosis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Earlier papers (2016–2020)1
  1. Management of Advanced Hepatic Alveolar Echinococcosis: Report of 42 Cases.2017The American journal of tropical medicine and hygiene

Run the PubMed searchClinicalTrials.gov

Other diseases

Idiopathic pulmonary fibrosis

特发性肺纤维化

Led 2 of the 989 English-language PubMed papers on idiopathic pulmonary fibrosis with an author in mainland China, 2021–2025: 0.2%.

Papers led
2
2021–2025
Trials led
1
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 1120222023: 0020232024: 0020242025: 112025

27 hospitals in Beijing for idiopathic pulmonary fibrosis333 hospitals in China for idiopathic pulmonary fibrosis

No open trial on idiopathic pulmonary fibrosis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Other diseases

Amyotrophic lateral sclerosis

肌萎缩侧索硬化症

Led 52 of the 779 English-language PubMed papers on amyotrophic lateral sclerosis with an author in mainland China, 2021–2025: 6.7%.

Papers led
52
2021–2025
Trials led
21
any status, ClinicalTrials.gov
Open trials led
2
recruiting or about to
Open trials as a site
2
led by another institution
Papers led per year
2021: 161620212022: 111120222023: 5520232024: 6620242025: 14142025

19 hospitals in Beijing for amyotrophic lateral sclerosis194 hospitals in China for amyotrophic lateral sclerosis

Open trials with this hospital 4

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 13 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    Clinical Study to Evaluate the Efficacy and Safety of FB1006 in the Treatment of ALS Patients
    Phase
    Phase 4
    Started
    2023-01
    Registry
    NCT05923905

    Age 18 years to 80 years (registered criteria)

    Led by Peking University Third HospitalBeijing

  2. Recruiting
    Natural History and Clinical Features of Amyotrophic Lateral Sclerosis (ALS)
    Phase
    Not given
    Started
    2019-11
    Registry
    NCT04454892

    Age not stated (registered criteria)

    Led by Peking University Third HospitalBeijing

  3. Recruiting
    A Study to Evaluate the Efficacy and Safety of Different Doses of CB03-154 in Adult Patients With Amyotrophic Lateral Sclerosis (ALS)
    Phase
    Phase 2/Phase 3
    Started
    2025-10
    Registry
    NCT07082192

    Age 18 years to 65 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing

  4. Recruiting
    The Safety, Tolerability and Preliminary Efficacy of Derived Motor Neuron Progenitor Cells (XS228CN) in Subjects With Amyotrophic Lateral Sclerosis
    Phase
    Phase 1
    Started
    2025-09
    Registry
    NCT07118319

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
Departments in papersNeurologyOphthalmology / neuro-ophthalmology
Papers it led52
  1. A rare genetic variant in APEX1 is associated with familial amyotrophic lateral sclerosis with slow progression.2025Acta neurologica Belgica
  2. Educational adjustments for the Chinese version of the Edinburgh Cognitive and Behavioral Screen (ECAS): establishing normative data.2025Amyotrophic lateral sclerosis & frontotemporal degeneration
  3. The contralateral co-movement test in a Chinese population with amyotrophic lateral sclerosis.2025Amyotrophic lateral sclerosis & frontotemporal degeneration
  4. Low CD3 level is a risk factor for amyotrophic lateral sclerosis: a Mendelian randomization study.2025Amyotrophic lateral sclerosis & frontotemporal degeneration
  5. Unveiling structural damage of the corpus callosum in amyotrophic lateral sclerosis through diffusion tensor imaging and spread direction perspectives.2025Annals of medicine
  6. Tetramethylpyrazine Nitrone in Amyotrophic Lateral Sclerosis: A Randomized Clinical Trial.2025JAMA network openRCT
  7. Exploring epigenetic modifications as potential biomarkers and therapeutic targets in amyotrophic lateral sclerosis.2025Journal of neurology
  8. Characteristics of Neuromuscular Ultrasound in Patients with Amyotrophic Lateral Sclerosis.2025Neuro-degenerative diseases
  9. Real-world evidence of riluzole on survival and ALSFRS change in a Chinese ALS cohort.2025Neurodegenerative disease management
  10. Characteristics and influencing factors of pain in amyotrophic lateral sclerosis: a focus on symptom management.2025Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology
  11. Two-step Mendelian randomization reveals a lipid-driven protective effect of type 2 diabetes on ALS.2025Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology
  12. Concomitant presence of a novel ARPP21 variant and CNVs in Chinese familial amyotrophic lateral sclerosis-frontotemporal dementia patients.2025Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology
  13. Amyotrophic Lateral Sclerosis With Concurrent LHON-associated m.14484T>C Mutation: A Case Report and Literature Review.2025Revista de neurologia
  14. The experience of pain symptoms in patients with amyotrophic lateral sclerosis: a qualitative study.2025Scientific reports
  15. Smell loss is associated with cognitive impairment in amyotrophic lateral sclerosis patients.2024CNS neuroscience & therapeutics
  16. Immune-mediated diseases are associated with a higher risk of ALS incidence: a prospective cohort study from the UK Biobank.2024Frontiers in immunology
  17. Whole-Genome Sequencing Identified a Novel Mutation in the N-Terminal Domain of KIF5A in Chinese Patients with Familial Amyotrophic Lateral Sclerosis.2024Genes
  18. Validation of the Center for Neurologic Study Bulbar Function Scale-Chinese version in a population with amyotrophic lateral sclerosis.2024Orphanet journal of rare diseases
  19. Lower creatinine-to-cystatin c ratio associated with increased risk of incident amyotrophic lateral sclerosis in the prospective UK biobank cohort.2024Scientific reports
  20. The integrity of the corticospinal tract and corpus callosum, and the risk of ALS: univariable and multivariable Mendelian randomization.2024Scientific reports
  21. Neutrophils Are Associated with Higher Risk of Incident Amyotrophic Lateral Sclerosis in a BMI- and Age-Dependent Manner.2023Annals of neurology
  22. Cost analysis of amyotrophic lateral-sclerosis management in China.2023Asian journal of surgery
  23. Lipids and amyotrophic lateral sclerosis: A two-sample Mendelian randomization study.2023European journal of neurology
  24. Mutation-specific metabolic profiles in presymptomatic amyotrophic lateral sclerosis.2023European journal of neurology
  25. Neutrophils: a subgroup of neglected immune cells in ALS.2023Frontiers in immunology
  26. A de novo c.113 T > C: p.L38R mutation of SPTLC1: case report of a girl with sporadic juvenile amyotrophic lateral sclerosis.2022Amyotrophic lateral sclerosis & frontotemporal degeneration
  27. An identical DCTN1 mutation in two Chinese siblings manifest as dHMN and ALS respectively: a case report.2022Amyotrophic lateral sclerosis & frontotemporal degeneration
  28. Human endogenous retrovirus K (HERV-K) env in neuronal extracellular vesicles: a new biomarker of motor neuron disease.2022Amyotrophic lateral sclerosis & frontotemporal degeneration
  29. Assessment of bidirectional relationships between 98 genera of the human gut microbiota and amyotrophic lateral sclerosis: a 2-sample Mendelian randomization study.2022BMC neurology
  30. Hypermetabolism associated with worse prognosis of amyotrophic lateral sclerosis.2022Journal of neurology
  31. Genotype-phenotype correlations in a chinese population with familial amyotrophic lateral sclerosis.2022Neurological research
  32. Dietary-Derived Essential Nutrients and Amyotrophic Lateral Sclerosis: A Two-Sample Mendelian Randomization Study.2022Nutrients
  33. Assessing the role of blood pressure in amyotrophic lateral sclerosis: a Mendelian randomization study.2022Orphanet journal of rare diseases
  34. Small fiber neuropathy for assessment of disease severity in amyotrophic lateral sclerosis: corneal confocal microscopy findings.2022Orphanet journal of rare diseases
  35. Association between type 2 diabetes and amyotrophic lateral sclerosis.2022Scientific reports
  36. Amyotrophic lateral sclerosis: new era, new challenges.2022The Lancet. Neurology
  37. Disease duration of progression is helpful in identifying isolated bulbar palsy of amyotrophic lateral sclerosis.2021BMC neurology
  38. Induced pluripotent stem cell-derived motor neurons from amyotrophic lateral sclerosis (ALS) patients carrying different superoxide dismutase 1 mutations recapitulate pathological features of ALS.2021Chinese medical journal
  39. Epidemiology and factors predicting survival of amyotrophic lateral sclerosis in a large Chinese cohort.2021Chinese medical journal
  40. Trends in the clinical features of amyotrophic lateral sclerosis: A 14-year Chinese cohort study.2021European journal of neurology
  41. Chinese validation of the Rasch-Built Overall Amyotrophic Lateral Sclerosis Disability Scale.2021European journal of neurology
  42. Daytime sleepiness might increase the risk of ALS: a 2-sample Mendelian randomization study.2021Journal of neurology
  43. Validation of the pathogenic role of rare DNAJC7 variants in Chinese patients with amyotrophic lateral sclerosis.2021Neurobiology of aging
  44. Physical activity and amyotrophic lateral sclerosis: a Mendelian randomization study.2021Neurobiology of aging
  45. GLT8D1 may not be significant in Chinese sporadic amyotrophic lateral sclerosis patients.2021Neurobiology of aging
  46. The complement C7 variant rs3792646 is associated with amyotrophic lateral sclerosis in a Han Chinese population.2021Neurobiology of aging
  47. TBK1 variants in Chinese patients with amyotrophic lateral sclerosis.2021Neurobiology of aging
  48. Leukocyte telomere length and amyotrophic lateral sclerosis: a Mendelian randomization study.2021Orphanet journal of rare diseases
  49. Prognosis of amyotrophic lateral sclerosis with cognitive and behavioural changes based on a sixty-month longitudinal follow-up.2021PloS one
  50. Loss of appetite in patients with amyotrophic lateral sclerosis is associated with weight loss and anxiety/depression.2021Scientific reports
  51. Myoglobin: a new biomarker for spinal and bulbar muscular atrophy?2021The International journal of neuroscience
  52. A natural history comparison of SOD1-mutant patients with amyotrophic lateral sclerosis between Chinese and German populations.2021Translational neurodegeneration
Chinese-language papers (not in the count)7
  1. [Progress in the application of uric acid-lowering treatments in amyotrophic lateral sclerosis].2023Zhonghua nei ke za zhi
  2. [Cortical thickness and cognitive impairment in patients with amyotrophic lateral sclerosis].2022Beijing da xue xue bao. Yi xue ban = Journal of Peking University. Health sciences
  3. [Genetic distribution in Chinese patients with hereditary peripheral neuropathy].2022Beijing da xue xue bao. Yi xue ban = Journal of Peking University. Health sciences
  4. [Cu/Zn superoxide dismutase and amyotrophic lateral sclerosis: a review of the current state of basic research and clinical trials].2022Zhonghua nei ke za zhi
  5. [Corneal confocal microscopy detects small-fiber neuropathy in patients with amyotrophic lateral sclerosis].2022Zhonghua nei ke za zhi
  6. [Rare variants of HSPB1 are probably associated with amyotrophic lateral sclerosis].2021Nan fang yi ke da xue xue bao = Journal of Southern Medical University
  7. [Association between rare UBQLN2 variants and amyotrophic lateral sclerosis in Chinese population].2021Zhonghua yi xue za zhi
Earlier papers (2016–2020)36
  1. The protective role of pre-morbid type 2 diabetes in patients with amyotrophic lateral sclerosis: a center-based survey in China.2020Amyotrophic lateral sclerosis & frontotemporal degeneration
  2. Twelve-month duration as an appropriate criterion for flail arm syndrome.2020Amyotrophic lateral sclerosis & frontotemporal degeneration
  3. Education, intelligence, and amyotrophic lateral sclerosis: A Mendelian randomization study.2020Annals of clinical and translational neurology
  4. Reply to "Life Course Adiposity and Amyotrophic Lateral Sclerosis".2020Annals of neurology
  5. Life Course Adiposity and Amyotrophic Lateral Sclerosis: A Mendelian Randomization Study.2020Annals of neurology
  6. Multicentre, prospective registry study of amyotrophic lateral sclerosis in mainland China (CHALSR): study protocol.2020BMJ open
  7. Anesthetic management of a parturient with amyotrophic lateral sclerosis undergoing cesarean section.2020Chinese medical journal
  8. Incidence and prevalence of amyotrophic lateral sclerosis in urban China: a national population-based study.2020Journal of neurology, neurosurgery, and psychiatry
  9. Whole-exome sequencing identified novel KIF5A mutations in Chinese patients with amyotrophic lateral sclerosis and Charcot-Marie-Tooth type 2.2020Journal of neurology, neurosurgery, and psychiatry
  10. Elevated cerebrospinal fluid homocysteine is associated with blood-brain barrier disruption in amyotrophic lateral sclerosis patients.2020Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology
  11. Changes in the concentrations of trimethylamine N-oxide (TMAO) and its precursors in patients with amyotrophic lateral sclerosis.2020Scientific reports
  12. [Decremental responses to repetitive nerve stimulation at slow rates in amyotrophic lateral sclerosis].2020Zhonghua nei ke za zhi
  13. Cognitive and behavioral impairments in German and Chinese ALS populations - a post-hoc comparison of national study data.2019Amyotrophic lateral sclerosis & frontotemporal degeneration
  14. Vestibular evoked myogenic potentials and their clinical utility in patients with amyotrophic lateral sclerosis.2019Clinical neurophysiology : official journal of the International Federation of Clinical Neurophysiology
  15. Two rare variants of the ANXA11 gene identified in Chinese patients with amyotrophic lateral sclerosis.2019Neurobiology of aging
  16. [Application value of motor unit number index in patients with amyotrophic lateral sclerosis].2019Zhonghua yi xue za zhi
  17. Identification of an A4V SOD1 mutation in a Chinese patient with amyotrophic lateral sclerosis without the A4V founder effect common in North America.2018Amyotrophic lateral sclerosis & frontotemporal degeneration
  18. Amyotrophic lateral sclerosis in Beijing: Epidemiologic features and prognosis from 2010 to 2015.2018Brain and behavior
  19. The epidemiology and genetics of Amyotrophic lateral sclerosis in China.2018Brain research
  20. Comparison of optical coherence tomography findings and visual field changes in patients with primary open-angle glaucoma and amyotrophic lateral sclerosis.2018Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia
  21. Screening for TUBA4A mutations in a large Chinese cohort of patients with ALS: re-evaluating the pathogenesis of TUBA4A in ALS.2018Journal of neurology, neurosurgery, and psychiatry
  22. Using the Capture-Recapture Method to Estimate the Incidence of Amyotrophic Lateral Sclerosis in Beijing, China.2018Neuroepidemiology
  23. A novel mutation of BICD2 gene associated with juvenile amyotrophic lateral sclerosis.2017Amyotrophic lateral sclerosis & frontotemporal degeneration
  24. Clinical Features of Isolated Bulbar Palsy of Amyotrophic Lateral Sclerosis in Chinese Population.2017Chinese medical journal
  25. Diets for Patients with Amyotrophic Lateral Sclerosis: Pay Attention to Nutritional Intervention.2017Chinese medical journal
  26. Whole-exome sequencing in amyotrophic lateral sclerosis suggests NEK1 is a risk gene in Chinese.2017Genome medicine
  27. CHCHD10 mutations in patients with amyotrophic lateral sclerosis in Mainland China.2017Neurobiology of aging
  28. DCTN1 gene analysis in Chinese patients with sporadic amyotrophic lateral sclerosis.2017PloS one
  29. No Evidence for Pathogenic Role of UBQLN2 Mutations in Sporadic Amyotrophic Lateral Sclerosis in the Mainland Chinese Population.2017PloS one
  30. Association Between Rectus Abdominis Denervation and Ventilation Dysfunction in Patients with Amyotrophic Lateral Sclerosis.2016Chinese medical journal
  31. Elimination Rate of Serum Lactate is Correlated with Amyotrophic Lateral Sclerosis Progression.2016Chinese medical journal
  32. MATR3 mutation analysis in a Chinese cohort with sporadic amyotrophic lateral sclerosis.2016Neurobiology of aging
  33. Two distinct clinical features and cognitive impairment in amyotrophic lateral sclerosis patients with TARDBP gene mutations in the Chinese population.2016Neurobiology of aging
  34. The presence of spontaneous EMG activity in sternocleidomastoid is associated with ventilatory dysfunction in ALS.2016Neurophysiologie clinique = Clinical neurophysiology
  35. The Edinburgh Cognitive and Behavioural ALS Screen in a Chinese Amyotrophic Lateral Sclerosis Population.2016PloS one
  36. [Association of serum uric acid level with amyotrophic lateral sclerosis].2016Zhonghua yi xue za zhi
All its trials on ClinicalTrials.gov, any status25
  1. Clinical Study to Evaluate the Efficacy and Safety of FB1006 in the Treatment of ALS PatientsRecruitingNCT05923905Lead sponsorPhase 4Start 2023-01
  2. Natural History and Clinical Features of Amyotrophic Lateral Sclerosis (ALS)RecruitingNCT04454892Lead sponsorStart 2019-11
  3. An IIT Clinical Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of a Single Intrathecal Injection of SNUG01 in Patients with Amyotrophic Lateral SclerosisNot yet recruitingNCT06645197Lead sponsorEarly phase 1Start 2024-10
  4. Pleiotropy and Mechanism of Peripheral Nerve Related Genes in the Progression of Amyotrophic Lateral SclerosisStatus unknownNCT04953494Lead sponsorStart 2021-08
  5. Home Care Needs and Current Nursing Status of Patients With Amyotrophic Lateral SclerosisStatus unknownNCT04953481Lead sponsorStart 2021-01
  6. Explore Biomarkers of Motor Neuron Disease/Frontal Dementia Spectrum Disease in ChinaEnrolling by invitationNCT04961450Lead sponsorStart 2021-06
  7. Sleep Disorders and the Onset and Progression of ALSStatus unknownNCT04952038Lead sponsorStart 2020-08
  8. Low Dose IL-2 in the Treatment of Immune-associated ALS SyndromeStatus unknownNCT04952155Lead sponsorPhase 2Start 2020-01
  9. Appetite and Related Factors in Patients With ALSStatus unknownNCT04953624Lead sponsorStart 2020-08
  10. Investigation on Home Care Needs of ALS Patients and Their CaregiversCompletedNCT04950231Lead sponsorStart 2020-09
  11. Efficacy and Safety of Nitrazine in the Treatment of ALSStatus unknownNCT04950647Lead sponsorPhase 2Start 2020-07
  12. Registration Study of Amyotrophic Lateral Sclerosis (ALS) in Mainland ChinaStatus unknownNCT04328675Lead sponsorStart 2020-03
  13. The Treatment of Amyotrophic Lateral Sclerosis With Huollingshengji GranulesStatus unknownNCT04950933Lead sponsorPhase 2/Phase 3Start 2020-06
  14. Multimodal Brain Imaging StudyStatus unknownNCT04960540Lead sponsorStart 2019-08
  15. Correlation Between Intestinal Microflora Metabolites and Amyotrophic Lateral SclerosisCompletedNCT04948346Lead sponsorStart 2018-01
  16. Application of Motor Unit Estimation Index in Amyotrophic Lateral Sclerosis and Related DiseasesStatus unknownNCT04956822Lead sponsorStart 2018-06
  17. Peripheral Neurofilament Levels and Amyotrophic Lateral SclerosisCompletedNCT04455542Lead sponsorStart 2017-08
  18. Treatment of Intravenous Infusion Plasma in Amyotrophic Lateral SclerosisCompletedNCT04454840Lead sponsorEarly phase 1Start 2016-05
  19. Quantitative Analysis of Precise Brain Volume in Amyotrophic Lateral SclerosisCompletedNCT04952025Lead sponsorStart 2015-01
  20. A Clinical Trial of Safety and Efficacy of Fasudil in Subjects With Amyotrophic Lateral Sclerosis (ALS)Status unknownNCT01935518Lead sponsorPhase 2Start 2013-09
  21. A Study to Learn More About the Long-Term Safety of Tofersen (Qalsody) in Chinese Participants With SOD-1 Amyotrophic Lateral Sclerosis (ALS)Active, not recruitingNCT07223723Lead (inferred)Phase 4Start 2025-12
  22. A Study to Evaluate the Efficacy and Safety of Different Doses of CB03-154 in Adult Patients With Amyotrophic Lateral Sclerosis (ALS)RecruitingNCT07082192Study sitePhase 2/Phase 3Start 2025-10
  23. The Safety, Tolerability and Preliminary Efficacy of Derived Motor Neuron Progenitor Cells (XS228CN) in Subjects With Amyotrophic Lateral SclerosisRecruitingNCT07118319Study sitePhase 1Start 2025-09
  24. A Phase Ⅰ/Ⅱa Study of SNUG01 in Adult Subjects With ALSNot yet recruitingNCT07169175Study sitePhase 1/Phase 2Start 2025-12
  25. Evaluate the Safety and Efficacy of Intrathecal Injection of RJK002 in Patients With Amyotrophic Lateral SclerosisActive, not recruitingNCT06493279Study sitePhase 1Start 2024-09

Run the PubMed searchClinicalTrials.gov

Other diseases

Spinal muscular atrophy

脊髓性肌萎缩症

Led no English-language PubMed papers on spinal muscular atrophy in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
2
any status, ClinicalTrials.gov
Open trials led
1
recruiting or about to
Open trials as a site
0
led by another institution

8 hospitals in Beijing for spinal muscular atrophy51 hospitals in China for spinal muscular atrophy

Open trials with this hospital 1

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 13 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    Effects of Different Stiffness Settings During Robotic Isokinetic Training in Children With SMA
    Phase
    N/A
    Started
    2026-10
    Registry
    NCT07822711

    Age 6 years to 12 years (registered criteria)

    Led by Peking University Third HospitalBeijing

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
Earlier papers (2016–2020)3
  1. [Midterm clinical outcomes and radiological results of surgical treatment for Hirayama disease].2017Beijing da xue xue bao. Yi xue ban = Journal of Peking University. Health sciences
  2. [Investigation of the compliance of cervical collar therapy in 73 patients with Hirayama disease].2016Zhonghua yi xue za zhi
  3. [Correlation of pre-operative factors with the outcome of surgical treatment of Hirayama disease].2016Zhonghua yi xue za zhi
All its trials on ClinicalTrials.gov, any status2
  1. Effects of Different Stiffness Settings During Robotic Isokinetic Training in Children With SMARecruitingNCT07822711Lead sponsorN/AStart 2026-10
  2. Robot-assisted TrainingCompletedNCT06648486Lead sponsorN/AStart 2025-02

Run the PubMed searchClinicalTrials.gov

Other diseases

Fabry disease

法布雷病

Led 1 of the 73 English-language PubMed papers on Fabry disease with an author in mainland China, 2021–2025: 1.4%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
1
led by another institution
Papers led per year
2021: 1120212022: 0020222023: 0020232024: 0020242025: 002025

11 hospitals in Beijing for Fabry disease85 hospitals in China for Fabry disease

Open trials with this hospital 1

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 13 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    A Study of Agalsidase Alfa Enyzme Replacement Therapy in Chinese Children and Adults With Fabry Disease
    Phase
    Not given
    Started
    2025-11
    Registry
    NCT07187440

    Age 7 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 18 listed hospitals as study sitesBeijing, Chengdu, Fuzhou, Hangzhou, Harbin, Hefei, Nanjing, Shantou, Shenzhen, Shijiazhuang, Suzhou, Taiyuan, Tianjin, Xi'an

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
Departments in papersNeurology

Run the PubMed searchClinicalTrials.gov

Other diseases

Duchenne muscular dystrophy

杜氏肌营养不良

Led 1 of the 213 English-language PubMed papers on Duchenne muscular dystrophy with an author in mainland China, 2021–2025: 0.5%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 1120212022: 0020222023: 0020232024: 0020242025: 002025

11 hospitals in Beijing for Duchenne muscular dystrophy116 hospitals in China for Duchenne muscular dystrophy

No open trial on Duchenne muscular dystrophy lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Other diseases

Behçet disease

白塞病

Led no English-language PubMed papers on Behçet disease in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
1
led by another institution

24 hospitals in Beijing for Behçet disease149 hospitals in China for Behçet disease

Open trials with this hospital 1

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 13 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    A Study of Efficacy and Safety of Hemay005 Tablets in Patients With Behçet's Disease
    Phase
    Phase 3
    Started
    2023-11
    Registry
    NCT06145893

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 20 listed hospitals as study sitesBeijing, Guangzhou, Guilin, Hangzhou, Linyi, Nanchang, Shanghai, Shenzhen, Shijiazhuang, Suzhou, Taiyuan, Wenzhou, Xiamen, Xuzhou

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
All its trials on ClinicalTrials.gov, any status1
  1. A Study of Efficacy and Safety of Hemay005 Tablets in Patients With Behçet's DiseaseRecruitingNCT06145893Study sitePhase 3Start 2023-11

Run the PubMed searchClinicalTrials.gov

Other diseases

IgA nephropathy

IgA 肾病

Led 1 of the 736 English-language PubMed papers on IgA nephropathy with an author in mainland China, 2021–2025: 0.1%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 0020242025: 112025

32 hospitals in Beijing for IgA nephropathy346 hospitals in China for IgA nephropathy

No open trial on IgA nephropathy lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersNephrology
Papers it led1
  1. IgA expressed by glomerular mesangial cells is involved in the pathogenesis of IgA nephropathy.2025Frontiers in immunology
Chinese-language papers (not in the count)1
  1. [Changes of gut microflora in newly diagnosed IgA nephropathy patients and its correlation with clinical risk factors].2023Beijing da xue xue bao. Yi xue ban = Journal of Peking University. Health sciences
Earlier papers (2016–2020)1
  1. Expression of immunoglobulin A in human mesangial cells and its effects on cell apoptosis and adhesion.2018Molecular medicine reports
All its trials on ClinicalTrials.gov, any status2
  1. TESTING -ON Post-Trial ObservatioNal Cohort StudyCompletedNCT05434325Study siteStart 2022-12
  2. Therapeutic Evaluation of Steroids in IgA Nephropathy Global Study (TESTING Low Dose Study)CompletedNCT01560052Study siteN/AStart 2012-05

Run the PubMed searchClinicalTrials.gov

Other diseases

Primary biliary cholangitis

原发性胆汁性胆管炎

Led no English-language PubMed papers on primary biliary cholangitis in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution

16 hospitals in Beijing for primary biliary cholangitis173 hospitals in China for primary biliary cholangitis

No open trial on primary biliary cholangitis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Earlier papers (2016–2020)1
  1. Dysregulation of Circulating Tfr/Tfh Ratio in Primary biliary cholangitis.2017Scandinavian journal of immunology

Run the PubMed searchClinicalTrials.gov

Other diseases

Familial adenomatous polyposis

家族性腺瘤性息肉病

Led no English-language PubMed papers on familial adenomatous polyposis in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution

7 hospitals in Beijing for familial adenomatous polyposis76 hospitals in China for familial adenomatous polyposis

No open trial on familial adenomatous polyposis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Earlier papers (2016–2020)1
  1. [Clinical and molecular characteristics of a child with familial adenomatous polyposis].2016Zhonghua er ke za zhi = Chinese journal of pediatrics

Run the PubMed searchClinicalTrials.gov

Getting in touch

Name card to show staff or a driver

北京大学第三医院

Peking University Third Hospital

北京

Large hospitals often have several campuses. Confirm the campus with the hospital before travelling.

Inquiry letter in English and Chinese

Fill in the brackets, then send it through the contact options on the hospital's international office or official website. Nothing typed here leaves this device.

Records hospitals usually ask for

  • A recent summary or letter from the treating doctor
  • Pathology report
  • Scans (CT, MRI, PET) with their reports, and the images if possible
  • Treatments so far, with dates
  • Current medicines

What to do next

Talk with the treating doctorThis page can be shared with the treating doctor to discuss whether this team's work is relevant.
Check the team is still therePapers lag by months and doctors move. Look at the hospital's own pages linked above.
Contact the hospital directlyUse the hospital's own contacts. Hospitals never pay us, and each hospital decides which patients it accepts.

Where these numbers come from

Papers

English-language PubMed papers whose first or last author lists this hospital as their first affiliation, 2021–2025. Definitions

Trials

ClinicalTrials.gov records naming this hospital as lead sponsor or site, as of 8 Nov 2026.

Identifiers and other names

ROR Wikidata
Peking University Third Hospital Cancer Center; Peking University Third Hospital (L.S.); Beijing Haidian Section of Peking University Third Hospital; PKU 3rd People's Hospital; PUTH; Sanyuan Hospital

Suggest a correctionDownload the data